Document:

EX-10.8

 CONFIDENTIAL TREATMENT REQUESTED 

Exhibit 10.8 

DISTRIBUTION AGREEMENT 

This DISTRIBUTION AGREEMENT (the “Agreement”), by and between AMEDICA CORPORATION, a Delaware corporation with a
principal place of business at 1885 West 2100 South, Salt Lake, City, Utah 84119 (“Amedica”) and Orthopaedic Synergy, Inc., a Delaware corporation with a principal place of business at 50 O’Connell Way #10, East Taunton, MA 02718 (the
“OSI”) is effective as of the 22nd day of February, 2010 (the “Effective Date”). Amedica and OSI are each referred to herein as a “Party” and collectively as the
“Parties.” 
 W I T N E S S E T H 

WHEREAS, Amedica designs and manufactures implantable orthopedic medical products and devices to be marketed, sold and distributed
worldwide; 
 WHEREAS, certain of Amedica’s products are manufactured utilizing a material known as Silicon Nitride
(“SiN”) which material is known to have particularly unique properties with respect to strength, wear, and bone ingrowth; 

WHEREAS, OSI manufacturers, markets, and sells implantable medical devices, including total hip and knee systems and related
instrumentation; 
 WHEREAS, OSI wishes to use certain of Amedica’s SiN components in the manufacture of certain of OSI’s
total implant systems; and 
 WHEREAS, Amedica desires to provide OSI with SiN components as more fully described herein pursuant to
the terms and conditions of this Agreement. 
 NOW THEREFORE, in consideration of the mutual agreements hereinafter set forth, the
Parties agree as follows: 
 1. DEFINITIONS. For the purpose of this Agreement, the following definitions will apply: 

a. “Product” or “Products” means Amedica’s SiN femoral head component in sizes to be determined by the Parties. 

b. “Territory” means all [***]. 

c. “OSI Hip System” means the total hip system into which the Products will be incorporated and which OSI will sell in the
Territory. 
 2. UNDERTAKINGS OF AMEDICA. Amedica agrees as follows: 

a. Product Supply. Amedica shall make [***] to supply OSI with quantities and sizes of the Products as requested by OSI pursuant to
written purchase orders. Purchase orders shall not be binding until accepted by Amedica and Amedica shall notify OSI promptly in the event that it rejects any purchase order. 

b. [***]. [***]. 
 c. Certain
Technical Information. Amedica will inform OSI in the event of any changes in indications, applications and/or contraindications or any recalls or restrictions of usage issued by any regulatory agency and applicable to any of the Products. 

d. Insurance. Amedica shall maintain products liability and other insurance in such amounts [***]. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 3. UNDERTAKINGS OF OSI. OSI agrees to: 

a. vigorously promote within the Territory the distribution and sale of the OSI Hip System in a manner that [***]; 

b. assist Amedica as may be needed from time to time to comply with all applicable laws and regulations regarding the tracking and
traceability of products and any other local applicable regulations in each and every jurisdiction where OSI sells the Products; and, comply with and keep Amedica timely advised with respect to all laws, licensing regulations and rulings of
governmental bodies having jurisdiction over OSI’s business concerning the sale of the Products; 
 c. exercise all necessary care in
storing the Products to insure their merchantability as safe and effective products, and maintain errors and omissions, general liability and all risk insurance in such amounts as are reasonably acceptable to Amedica and provide proof of such
insurance to Amedica upon request; 
 d. advise Amedica of any suit, claim, complaint or performance issues known to OSI resulting from the
sale or use of any of the Products, as well as any recalls or restrictions of usage issued by a regulatory agency; 
 e. provide samples of
all marketing and promotional materials which relate in any way to the Products to Amedica for Amedica’s prior approval, which approval shall not be unreasonably withheld; 

4. TERM AND TERMINATION. 
 a.
Subject to the termination rights contained in this Agreement, the initial term of this Agreement shall be for period of five (5) years commencing on the Effective Date. Thereafter, the Parties may agree to extend the Agreement provided such
agreement is committed to writing and signed by authorized representatives of both Parties. 
 b. This Agreement may be terminated for any
of the following reasons: 
 (i) by either Party in the event that the other party breaches this Agreement and fails to cure such breach
within thirty (30) days of its receipt of written notice from the non-breaching Party specifying the details of such breach; 
 (ii) by
Amedica in the event that OSI fails to exercise reasonable best efforts in the distribution and sale of the Products pursuant to this Agreement; 

(iii) either Party, by written notice to the other, may terminate this Agreement immediately if either Amedica or OSI (as applicable):
(A) [***] its business, (B) becomes subject to any bankruptcy or insolvency proceeding under federal or state law, (C) becomes insolvent or becomes subject to direct control by a trustee, receiver or similar authority, or (D) has
wound up or liquidated its business voluntarily or otherwise; 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

  
 2 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (iv) immediately by either Party if the other Party intentionally engages in wrongful acts
which materially impair the goodwill or business of Amedica or cause material damage to Amedica’s property, goodwill, or business; and 

(v) immediately by either Party and upon written notice to the other in the event that a Party (or any of a Party’s members,
shareholders, directors, managers, employees or agents) is excluded from, debarred or otherwise subject to sanctions by the Medicare or Medicaid programs or is assessed any civil or criminal fines or penalties under such programs or under federal or
state anti-kickback or Stark laws. 
 c. Any termination of this Agreement shall constitute a cancellation of all orders from OSI, whether
received prior to or after such termination, but shall [***] which OSI may then have with Amedica; provided however, that after termination of this Agreement, OSI shall have the right to distribute and/or sell Products [***] or [***] until such
products [***] or [***], whichever occurs first. Upon any such termination of this Agreement, Amedica shall [***] in any manner whatsoever on account of such [***]; furthermore, Amedica shall not, for any reason whatsoever, including but not limited
to the breach, termination, cancellation or expiration of this Agreement, [***],[***], either on account of [***] or on account of any other thing or cause whatsoever, including, without limitation, [***], whether arising out of warranty or other
contract, negligence or other tort, or otherwise. 
 5. INTELLECTUAL PROPERTY RIGHTS; COMPETING PRODUCTS; CONFIDENTIAL INFORMATION. The
Parties agree that all trademarks, copyrights, patents, trade secrets, service marks, trade dress and other intellectual property and/or proprietary rights of Amedica and/or associated with the Products (the “Intellectual Property Rights”)
are the sole and exclusive property of Amedica unless otherwise provided herein or in that certain Joint Development Agreement executed by the Parties and dated February 8, 2010. No action of Amedica or any provision in this Agreement shall, at
any time, be deemed as transferring any Intellectual Property Rights of Amedica to OSI or creating any other right in or to such Intellectual Property Rights in OSI. 

6. TERMS AND CONDITIONS. 
 a.
Pricing and Revenue Share. The Parties shall mutually agree on pricing for the OSI Hip System into which the Products are incorporated, which pricing shall depend upon all reasonable and customary factors including without limitation
geographical area, availability of discounts and/or rebates, etc. Individual component pricing for the Products shall be agreed upon between the Parties prior to any sale to any third Party. All prices shall be committed to writing. The Parties
shall share equally the Net Margin amount for each Product. Net Margin is defined as the actual sales price of each Product less (i) discounts and/or rebates; (ii) usual and customary manufacturing costs of all components, which costs
shall be invoiced as provided in Section 6(c) below; (iii) commissions paid to sales personnel; and (iv) delivery costs. 

b. Right to Audit. Either Party will have the right to audit all cost calculations upon reasonable notice in writing to the
other Party, however in no event shall such right to audit be exercised more than once per calendar year. In the event that an audit evidences that such costs have been figured incorrectly and to the detriment of the Party requesting the audit,
[***]. 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

  
 3 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 c. Invoicing upon Shipment. Amedica shall invoice OSI [***] upon shipment of
same to OSI. Payment for all such invoices shall be [***] from the date on each invoice presented to OSI by Amedica. 
 d. Quarterly
[***] Reconciliation. Within [***] of the end of each calendar quarter, OSI shall provide to Amedica a reconciliation of the [***] sold during each such calendar quarter. Payment due Amedica as evidenced by each reconciliation report
shall be included with each reconciliation forwarded to Amedica pursuant to this Section 6(d). 
 e. Orders and
Deliveries. All orders received by Amedica from OSI are subject to written acceptance by Amedica. Amedica may reject any order which it receives from OSI. OSI shall provide shipping instructions to Amedica. 

7. PRODUCT WARRANTIES AND LIMITATIONS ON DAMAGES. OSI shall make no warranty or representation with respect to Amedica or any of the Products,
whether express or implied, unless first approved by Amedica in writing, and in such case, provided that OSI shall be solely responsible for any claims made under, or with respect to, any such warranty. Amedica will likewise make no warranty or
representation with respect to OSI’s product offerings. 
 8. PRODUCT IDENTIFICATION. All Products incorporated into the OSI Hip System
and sold by OSI shall name Amedica as manufacturer of the Products.  
 9. INDEMNITY. 

a. By Amedica. To the extent not otherwise covered by insurance, Amedica shall defend, indemnify and hold harmless OSI from and
against any liabilities, losses, damages, costs and expenses (including reasonable attorney fees and other costs and expenses) arising out of: (i) any claim or action brought against OSI for any claim that the Products infringe any United
States patent, copyright, trademark or trade secret under United States law, provided that, OSI promptly notifies Amedica in writing of such claim and allows Amedica to control, and fully cooperates with Amedica in, the defense of any such claim or
action and any settlement negotiations related thereto. Notwithstanding the above, Amedica shall have no liability for any settlement or compromise made without its express written consent. In the event of a claimed infringement, Amedica reserves
the right to do any of the following: replace the Product with a non-infringing product or a product of equivalent functionality; modify the Product to make it non-infringing; procure for OSI the right to continue using said Product; or remove the
Product and refund the price paid to Amedica for such Product. The foregoing constitutes Amedica’s entire liability in the event of any claim of intellectual property infringement. 

b. By OSI. OSI shall defend, indemnify and hold harmless Amedica from and against any claim, liabilities, losses, damages, costs
and expenses (including reasonable attorney fees and other costs and expenses) associated with any claim or action that arises out of or relates to: (i) any acts or omissions of OSI or its employees, agents or other representatives;
(ii) any claims arising from the marketing, promotion or distribution of the Products by OSI or its employees, agents or other representatives; (ii) any failure of OSI, or its employees, agents or other representatives, to comply with any
obligation under this Agreement; (iii) any claim that arises out of any promises, representations or warranties that OSI, or its employees, agents or other representatives, make to customers or other persons or entities, express, implied or
otherwise; (iv) any claim arising out of any sale by OSI or its employees, agents or other 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

  
 4 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
representatives (except to the extent caused by Amedica’s errors or omissions); or (v) any unauthorized use of the Products by any party obtaining the Products from OSI or its
employees, agents or other representatives. 
 10. RECORD KEEPING; INSPECTION. OSI shall keep accurate, up-to-date records of all its transactions in purchasing and selling the Products, including, [***]. Such records shall be retained for at least a period of four (4) years following such record year,
which record retention requirement shall survive the termination of this Agreement. [***], Amedica (and/or its designated agent) shall have the right to visit and inspect the place of business of OSI and to inspect such books at OSI’s principal
place of business during normal business hours during the Term of this Agreement and for a period of [***] following the termination or expiration of this Agreement. 

11. MISCELLANEOUS. 
 a.
Entire Agreement and Modification. This Agreement and the exhibits attached hereto constitute the entire understanding between the parties with respect to the subject matter hereof and supersedes all prior contemporaneous discussions,
agreements or representations, written or oral, concerning the subject matter of this Agreement. No modification or amendment of this Agreement shall be binding unless in writing signed by both parties hereto. 

b. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware,
without regard to conflict of law provisions. 
 c. Waiver. No waiver of any provision of this Agreement shall be valid unless
the same is in writing and signed by the party against whom such waiver is to be enforced. No failure, neglect or delay by a party to enforce any provision of this Agreement shall at any time be deemed a waiver of any other provision of this
Agreement at such time or shall be deemed a waiver of such provision at any other time. Failure to enforce any provision of this Agreement, by either party, shall not be construed as a waiver of that provision. 

d. Notice. Any notice or communication required or permitted to be given under this Agreement shall be in writing and shall be
served on the Parties at the address of the recipient Party listed above or to such other address, as any Party may by written notice designate. Any notice or communication required, permitted or desired to be given by any provision of this
Agreement shall be sent either (i) by prepaid certified or registered mail, return receipt requested, in which case notice shall be deemed received three business days after deposit, postage prepaid in the United States Mail; (ii) by
nationally recognized overnight courier, in which case notice shall be deemed received one business day after deposit with such courier provided that such courier has written evidence of delivery to such Party’s address; or (iii) by
facsimile with appropriate electronic confirmation or receipt. 
 e. Surviving Provisions. The Parties expressly agree that
the provisions contained in Section 6 regarding Price and Revenue Sharing relative to the Products shall survive the expiration and/or earlier termination of this Agreement unless otherwise agreed by the Parties or in the event of a breach of
this Agreement by either Party. Additionally, the provisions of Section 5, 7, 6, 9, 10, and 11 shall survive the expiration of earlier termination of this Agreement. 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

  
 5 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 f. Assignment. This Agreement is non-transferable except as permitted in this
paragraph. Either Party to this Agreement may assign its interest under this Agreement to any entity controlling, controlled by or under common control with such Party or an entity which is succeeding to the entire business of Company; provided,
however, that either Party must assign its rights and obligations under this Agreement to any purchaser of all or substantially all of the assets of said Party, in which case the purchaser shall remain liable for all of such Party’s obligations
hereunder. 
 g. Relationship of the Parties. Nothing in this Agreement is intended to create an exclusive business
relationship between the Parties except as set out herein, nor will this Agreement be deemed or construed to constitute or create between the Parties a partnership, joint venture, agency, or other legal business entity. 

h. Provision Rendered Invalid. If any provision of this Agreement is invalid, illegal or incapable of being enforced under any
rule of law or public policy, Amedica may terminate this Agreement forthwith or, at its option, continue the Agreement as so modified by law or policy. 

i. Force Majeure. If during the term of this Agreement an event of force majeure should prevent either party from fulfilling
contractual obligations, the party so affected shall be excused from any liability for non-performance during the period of such force majeure; provided however, if such force majeure continues for more than thirty [***] then either party may
terminate this Agreement. 
 j. Ability to Contract. The Parties represent and warrant to each other that they are not
prohibited from entering into this Agreement, selling the Products or otherwise conducting business with each other as contemplated herein, whether due to any contract to which either is a party, or other commitment or obligation binding on either
party. 
 k. Production. Nothing herein shall be deemed to require that Amedica continue the production of any Product.
Amedica shall not be liable for delays in delivery or failure to perform any obligation hereunder due to force majeure or any other cause beyond its control, including, but not limited to, vendor problems, labor disputes, acts of war or terrorism,
fire, delays in transportation or shortages of materials or transportation supplies. 
 l. Confidential Nature of Terms and
Provisions. The Parties acknowledge and agree that the terms and provisions of this Agreement are confidential in nature and not to be disseminated to any third party unless required by law, court order, or other legal mandate.
Notwithstanding the foregoing, the parties are free to reference the existence of the business relationships between them in press releases, company websites, and any other public forum provided that such information publicly disclosed be limited to
the fact that the parties have entered into an agreement and the products made the subject matter of that agreement. 
 m. Multiple
Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original instrument, but both such counterparts together shall constitute but one agreement. 

n. Compliance with Laws and Regulations. The Parties represent and warrant that they: (i) will not violate or cause the
other Party to violate any provision of United States law; (ii) shall comply at all times with all worldwide applicable laws, including, without limitation, those related to medical devices, health care fraud and abuse and all federal and state
health care reimbursement programs, 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

  
 6 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
advertising, warranties, environmental concerns, national security, registration of commercial representatives, and employment; (iii) shall comply with the regulatory requirements of each
jurisdiction in which the Products are sold, to the extent that the same apply to the parties’ respective obligations under this Agreement. 

NOW THEREFORE, the undersigned have executed this Agreement as of the Effective Date. 

 

			
	AMEDICA CORPORATION
	
	 /s/ Ben R. Shappley

	Ben R. Shappley, CEO
	
	ORTHOPAEDIC SYNERGY, INC.
		
	Its:	 	 /s/ R.D. Nikolaev, CEO

	
	 R.D. Nikolaev, CEO

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

  
 7 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 FIRST AMENDMENT AND ADDENDUM 

TO DISTRIBUTION AGREEMENT 
  

			
	DATED:	 	To be Effective as of November 1, 2012 (the “Amendment Date”).
		
	PARTIES:	 	The Parties, each individually a “Party”, to this First Amendment and Addendum to Distribution Agreement (herein the “First Amendment”) are:

  

	 	(a)	Orthopeadic Synergy Inc., a Delaware corporation (“OSI”); 

  

	 	(b)	Amedica Corporation, (“Amedica”). OSI and Amedica are collectively referred to as the “Parties.” 

RECITALS 
 OSI and Amedica
entered into that certain Distribution Agreement dated February 22, 2010 (the “Agreement”). All capitalized terms in the Agreement which are not defined in this First Amendment will have the definitions ascribed to them in the
Agreement. 
 OSI and Amedica desire to amend the Agreement, as more particularly set forth in this First Amendment. 

The Parties therefore agree as follows: 
  

	 	1.	Incorporation of Recitals. All of the forgoing Recitals are hereby incorporated as agreements of the Parties. 

  

	 	2.	Amendments to the Agreement. OSI and Amedica hereby amend the Agreement as follows: 

  

	 	A.	Section 1(b), in the Definition Section of the Agreement is replaced by the following Section 1(b), which amends, supersedes and replaces Section 1(b) of the Agreement in its entirety: 

 

	 	b.	“Territory” means all countries in the world, including the USA. 

  

	 	B.	Section 2(a), in the Definition Section of the Agreement is replaced by the following Section 2(a), which amends, supersedes and replaces Section 2(a) of the Agreement in its entirety: 

 

	 	2(a)	 Distribution Product Supply. Subject to the terms and conditions of this Agreement, Amedica shall use reasonable efforts to supply
OSI with quantities and sizes of the Products as requested by OSI pursuant to written purchase orders. Specifically, Amedica agrees to 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	
provide OSI with all requested Products before providing [***] to any other customer of Amedica. Purchase orders shall not be binding on Amedica until accepted by Amedica and
Amedica shall notify OSI promptly in the event that it rejects any purchase order which Amedica may do in the event [***]. 

  

	 	C.	Section 4(a) of the Agreement is replaced by the following Section 4(a), which amends, supersedes and replaces Section 4(a) of the Agreement in its entirety: 

 

	 	4(a)	Term. The term of this Agreement shall begin upon the Effective Date and expire eight (8) years from regulatory approval or clearance of the Product unless earlier terminated (the “Term”).
The Parties shall be free to mutually agree to any extension or renewal of this Agreement to the extent that same is memorialized in writing and signed by both Parties. 

 

	 	D.	Sections 6(a), 6(b), 6(c) and 6(d) of the Agreement are replaced by the following Section 6(a-d), which amends, supersedes and replaces Sections 6(a), 6(b), 6(c) and 6(d) of the Agreement in their entirety:

  

	 	(a-d)	Pricing: The Parties agree that the pricing of the Products will [***]. 

  

	 	E.	Section 9(b) of the Agreement is replaced by the following Section 9(b), which amends, supersedes and replaces Section 9(b) of the Agreement in its entirety: 

 

	 	9(b)	 By OSI. OSI shall defend, indemnify and hold harmless Amedica from and against any claim, liabilities, losses, damages, costs and
expenses (including reasonable attorney fees and other costs and expenses) associated with any claim or action that arises out of or relates to: (i) any acts or omissions of OSI or its employees, agents or other representatives; (ii) any
claims arising from the marketing, promotion or distribution of the Products by OSI or its employees, agents or other representatives; (iii) any failure of OSI, or its employees, agents or other representatives to comply with any obligation
under this Agreement; (iv) any claim that arises out of any promises, representations or warranties that OSI, or its employees, agents or other representatives, make to customers or other persons or entities, express, implied or

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	
otherwise; (v) any claim arising out of any sale by OSI or its employees, agents or other representatives (except to the extent caused by Amedica’s errors or omissions); (vi) any
unauthorized use of the Products by any party obtaining the Products from OSI or its employees, agents or other representatives; or (vii) any claim that the OSI Hip System infringes any United States patent, copyright, trademark or trade secret
under United States law. 

  

	 	3.	Addendums to the Agreement: OSI and Amedica hereby addend the Agreement as follows: 

  

	 	A.	The following Section, 3(f), is added by Addendum to the Agreement in its entirety: 

  

	 	 f.	Regulatory Submission: SiN on Polyethylene 

  

	 	(i)	510(k) Application: The Parties wish to proceed with a 510(k) application (the “510(k)”) for the application of SiN with polyethylene. [***]. 

 

	 	(ii)	Ownership of 510(k). The 510(k) shall be owned by [***] to the extent permitted by law and the regulatory authorities, the rights, responsibilities, obligations with respect to the 510(k).

  

	 	B.	The following Section, 3(g), is added by Addendum to the Agreement in its entirety: 

  

	 	3(g)	Exclusivity Period: Amedica agrees that for a period of [***], which time period shall begin to run upon the Product’s [***] in the US market (the “Exclusive License
Period”), Amedica shall not [***] or otherwise [***] the SiN technology embodied in each such Product to any third party for use in hip and/or knee systems or components, worldwide. 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	C.	The following Section, 11(o), is added by Addendum to the Agreement in its entirety: 

  

	 	(o):	Change of Control: In the event of a Change of Control as defined herein, the Parties acknowledge and agree that any successor entity to either Amedica or OSI shall be bound by each and every of the terms
and provisions of this Agreement and that any failure of a successor entity to abide by same shall be considered a material breach of this Agreement. 

For purposes of this Agreement, Change of Control means: 

(i) any public report or notice is filed with any authority in the United States, or any public announcement is made, that discloses
that any person has become the beneficial owner, directly or indirectly, of 50 percent or more of the outstanding voting stock of Amedica or OSI; 

(ii) any person purchases securities pursuant to an offer for cash or exchange of securities to acquire any voting stock of Amedica or
OSI (or any securities convertible into voting stock of Amedica or OSI) and, immediately after consummation of that purchase, that person is the beneficial owner, directly or indirectly, of 50 percent or more of the outstanding voting stock of
Amedica or OSI; 
 (iii) the consummation of 

(a) a merger, stock exchange plan, consolidation or reorganization of Amedica or OSI with or into any other person if as a result of
such merger, stock exchange plan, consolidation or reorganization, less than 50 percent of the combined voting power of the then-outstanding securities of such other person immediately after such merger, consolidation or reorganization are held in
the aggregate by the holders of voting stock of Amedica or OSI immediately prior to such merger, stock exchange plan, consolidation or reorganization; 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (b) any sale, lease, exchange or other transfer of all or substantially all the assets
of Amedica or OSI and their respective consolidated subsidiaries to any other person if as a result of such sale, lease, exchange or other transfer, less than 50 percent of the combined voting power of the then-outstanding securities of such other
person immediately after such sale, lease, exchange or other transfer are held in the aggregate by the holders of voting stock of Amedica or OSI immediately prior to such sale, lease, exchange or other transfer; or 

(c) a transaction immediately after the consummation of which any person (within the meaning of Section 13(d) or Section l4(d)(2)
of the Exchange Act) would be the beneficial owner (as that term is defined in Rule 13d-3or any successor rule or regulation promulgated under the Exchange Act), directly or indirectly, of more than 50 percent of the outstanding voting stock of
Amedica or OSI; or 
  

	 	(iv)	the dissolution of Amedica or OSI is approved in accordance with the laws of the  jurisdiction of formation of the respective Party. 

 

	 	4.	No Other Amendments. Except as provided in Section 2 and 3 of this First Amendment, the terms and provisions of the Agreement remain unmodified and in full force and effect. 

 

	 	5.	Counterparts And Facsimile Signatures. This First Amendment may be executed in multiple counterparts, each of which is an original for any and all purposes and all of which together shall constitute one and the
same instrument, and facsimile signatures shall be deemed sufficient to bind either Party hereto. 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, the Parties have executed this First Amendment as of the Amendment Date.

  

									
	Orthopaedic Synergy, Inc.	 		 	Amedica Corporation
					
	By:	 	/s/ [Illegible]	 		 	By:	 	/s/ Eric K. Olson
	  
	 		 	  

	Name:	 	Illegible	 		 	Name:	 	Eric K. Olson
	Title:	 		 		 	Title:	 	President / CEO

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended.EX-10.13.1

 Exhibit 10.13.1 

Award No. RSU-150 
 AMEDICA
CORPORATION 
 Restricted Stock Unit Award Notice 

under the Company’s 
 2012
Employee, Director and Consultant 
 Equity Incentive Plan 
  

					
	1.	  	Name and Address of Participant:	  	Jay Moyes
		  		  	1633 Stone Ridge Drive
		  		  	Bountiful, UT 84010
			
	2.	  	Date of Award:	  	October 30, 2013
			
	3.	  	Type of Grant:	  	Restricted Stock Unit
			
	4.	  	Number of RSUs:	  	1,500,000

 Amedica Corporation, a Delaware corporation (the “Company”) hereby grants to the above named Participant the
aggregate number of RSUs shown above (the “Restricted Stock Unit Award”) which represents a contingent entitlement of the Participant to receive shares of the Company’s common stock, on the terms and conditions and subject to all the
limitations set forth herein and in the 2012 Employee, Director and Consultant Equity Incentive Plan (the “Plan”), which is incorporated herein by reference. The Participant acknowledges receipt of a copy of the Plan. 

The Company and the Participant hereby acknowledge receipt of this Grant and agree to the terms of the Restricted Stock Unit Agreement attached hereto and
incorporated by reference herein, the Plan and the terms of this Restricted Stock Unit Award as set forth above. 
  

			
	AMEDICA CORPORATION
		
	By:	 	 /s/ Kevin Ontiveros

	Name:	 	Kevin Ontiveros
	Title:	 	Chief Legal Officer
	
	PARTICIPANT:
		
		 	 /s/ Jay Moyes

		 	Jay Moyes

 RESTRICTED STOCK UNIT AGREEMENT 

AMEDICA CORPORATION 
 NOW,
THEREFORE, in consideration of the promises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

1. Grant of Award. The Company hereby grants to the Participant an aggregate number of RSUs as set forth in the Restricted Stock Unit
Award Notice (the “Award”) which represents a contingent entitlement of the Participant to receive shares of Common Stock, on the terms and conditions and subject to all the limitations set forth herein and in the Plan, which is
incorporated herein by reference. The Participant acknowledges receipt of a copy of the Plan. The Company and the Participant understand and agree that any terms used and not defined herein have the meanings ascribed to such terms in the Plan. 

2. Vesting and Forfeiture of Award. The Award granted hereby shall become vested as to the number of RSUs set forth below as of the
applicable Event Vesting Date provided that the Participant is employed by the Company on the Event Vesting Date: 
  

					
	 Event Vesting Date
	  	Number of RSUs	 
	 On the first day of Participant’s employment with the Company
	  	 	500,000 units	  
		
	 Upon the successful restructuring of GE capital debt provided that such event occurs prior to January 31, 2014
	  	 	500,000 units	  
		
	 Upon the pricing of an IPO provided that such event occurs prior to June 30, 2014
	  	 	500,000 units	  

 As of the date on which the Participant’s employment with the Company terminates, all unvested RSUs subject to the Award
shall immediately be forfeited to the Company. 
 Notwithstanding the foregoing, the Award shall be deemed fully vested as to all of the RSUs subject to the
Award upon the first to occur of the following events: 
 (i) On the day of and immediately prior to a Change in Control (as defined below)
provided that the Participant is employed by the Company or an Affiliate on such date; or 
 (ii) On the day of a termination of
Executive’s employment due to Executive’s Disability (as defined below) or death. 
 “Change of Control” means any
person (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) becomes the “beneficial owner” (as defined in Rule 13d-3 under the Act), directly or indirectly, of
securities of the Company representing 50% or more of the total voting power represented by the Company’s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its Affiliates or by any
employee benefit plan of the Company) pursuant to a transaction or a series of related transactions of which the Board does not approve; (ii) a merger or consolidation of the Company, whether or not approved by the Board, other than a merger or
consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the
parent of 

  
 2 

 
such corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be,
outstanding immediately after such merger or consolidation; or (iii) the stockholders of the Company approve an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets. “Change in
Control” shall be interpreted in a manner, and limited to the extent necessary, so that it will not cause adverse tax consequences for either party with respect to Section 409A of the Code and the rules and regulations thereunder
(“Section 409A”). 
 “Disability” shall mean the inability of the Participant to perform the principal functions of his
duties due to a physical or mental impairment, but only if such inability has lasted or is reasonably expected to last for at least sixty (60) consecutive days or an aggregate of one hundred twenty (120) days during any twelve-month
period. Whether the Participant has a Disability will be determined by a majority of the Board based on evidence provided by one or more physicians selected by the Board and approved by the Participant, which approval shall not be unreasonably
withheld. 
 (c) Issuance of Shares. The Participant shall not be entitled to receive shares for any vested RSUs until the first to
occur of the following (the “Release Date”): 
 (i) A Change in Control; or 

(ii) a separation from service from the Company for any reason in compliance with Section 409A of the Code. 

Subject to Section 8 hereof, the Company shall issue on the Release Date to the Participant (or, in the event of the Participant’s death, to the
Participant’s Survivor) in certificated or uncertificated form shares of Common Stock equal to the number of vested RSUs. Notwithstanding the foregoing, if the Participant is deemed at the time of the Participant’s separation from service
to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, the issuance of the shares of Common Stock may be delayed in order to avoid an additional tax under Section 409A(a)(1)(B) of the Code and the
shares of Common Stock shall not be issued to the Participant until the earlier of (a) the first business day following the expiration of the six-month period measured from the date of the Participant’s separation from service,
(b) the date of the Participant’s death, or (c) such earlier date that shall avoid the imposition of the additional tax under Section 409A(a)(1)(B).

3. Limitations on Transfer and Sale. 

(a) Prohibitions on Transfer of Award. This Award (including any additional RSUs received by the Participant as a result of stock
dividends, stock splits or any other similar transaction affecting the Company’s securities without receipt of consideration) shall not be transferable by the Participant otherwise than by will or by the laws of descent and distribution or
pursuant to a qualified domestic relations order as defined by the Code or Title I of the Employee Retirement Income Security Act or the rules thereunder. Except as provided in the previous sentence, the shares of Common Stock to be issued pursuant
to this Agreement shall be issued, during the Participant’s lifetime, only to the Participant (or, in the event of legal incapacity or incompetence, to the Participant’s guardian or representative). This Award shall not be assigned,
pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of this Award or of
any rights granted hereunder contrary to the provisions of this Section 3, or the levy of any attachment or similar process upon this Award shall be null and void. 

(b) Limitations on Sale of Shares. The shares of Common Stock issued to the Participant hereunder (the “Issued Shares”) shall
not be transferred by the Participant except as permitted in this Section 3 and Section 5. 

  
 3 

 (c) The Participant agrees that in the event the Company proposes to offer for sale to the public
any of its equity securities and such Participant is requested by the Company and any underwriter engaged by the Company in connection with such offering to sign an agreement restricting the sale or other transfer of the shares of Common Stock (or
any shares into which such Common Stock has been converted), then it will promptly sign such agreement and will not transfer, whether in privately negotiated transactions or to the public in open market transactions or otherwise, any shares of
Common Stock or other securities of the Company held by him or her during such period as is determined by the Company and the underwriters, not to exceed 180 days following the closing of the offering, plus such additional period of time as may be
required to comply with NASD Marketplace Rule 2711 or similar rules thereto (such period, the “Lock-Up Period”). Such agreement shall be in writing and in form and substance reasonably satisfactory to the Company and such underwriter and
pursuant to customary and prevailing terms and conditions. Notwithstanding whether the Participant has signed such an agreement, the Company may impose stop-transfer instructions with respect to the shares of Common Stock or other securities of the
Company subject to the foregoing restrictions until the end of the Lock-Up Period. 
 (d) The Participant acknowledges and agrees that
neither the Company nor, its shareholders nor its directors and officers, has any duty or obligation to disclose to the Participant any material information regarding the business of the Company or affecting the value of the shares of Common Stock
before, at the time of, or following the Participant’s termination, including, without limitation, any information concerning plans for the Company to make a public offering of its securities or to be acquired by or merged with or into another
firm or entity. 
 4. Adjustments. The Plan contains provisions covering the treatment of RSUs and shares of Common Stock in a number
of contingencies such as stock splits and mergers. Provisions in the Plan for adjustment with respect to this Award and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are
incorporated herein by reference. 
 5. Purchase for Investment; Securities Law Compliance. The Participant hereby represents and
warrants that he or she is acquiring the RSUs for his or her own account, for investment, and not with a view to, or for sale in connection with, the distribution of any Common Stock. The Participant specifically acknowledges and agrees that any
sales of Common Stock shall be made in accordance with the requirements of the Securities Act of 1933, as amended, in a transaction as to which the Company shall have received an opinion of counsel satisfactory to it confirming such compliance. The
Participant shall be bound by the provisions of the following legend which shall be endorsed upon the certificate(s) evidencing the Common Stock: 

“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN TAKEN FOR INVESTMENT AND THEY MAY NOT BE SOLD OR OTHERWISE TRANSFERRED BY ANY
PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION STATEMENT WITH RESPECT TO SUCH SHARES SHALL BE EFFECTIVE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSEL
SATISFACTORY TO IT THAT AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT IS THEN AVAILABLE, AND (2) THERE SHALL HAVE BEEN COMPLIANCE WITH ALL APPLICABLE STATE SECURITIES LAWS.” 

The Participant acknowledges that if the Participant is not a United States employee, he or she has been informed that the Common Stock or
other securities of the Company to be received by the Participant under this Agreement are subject to restrictions on resale under securities laws applicable to such Participant based on the jurisdiction of such Participant. The Participant agrees
not to sell any such Common Stock or other securities except in accordance with such laws. 

  
 4 

 6. Rights as a Stockholder. The Participant shall have no right as a stockholder,
including voting and dividend rights, with respect to the RSUs subject to this Agreement. 
 7. Incorporation of the Plan. The
Participant specifically understands and agrees that this Award and the shares of Common Stock to be issued under the Plan are being issued to the Participant pursuant to the Plan, a copy of which Plan the Participant acknowledges he or she has read
and understands and by which Plan he or she agrees to be bound. The provisions of the Plan are incorporated herein by reference. 
 8.
Tax Liability of the Participant and Payment of Taxes. 
 The Participant acknowledges and agrees that any income or other taxes,
fees or other amounts due from the Participant with respect to this Award or the shares of Common Stock to be issued pursuant to this Agreement or otherwise sold shall be the Participant’s responsibility. The Participant shall pay to the
Company, or make provision satisfactory to the Company for payment of, any taxes or other amounts required to be withheld by the Company in accordance with applicable law or regulation no later than the date of the event creating the tax liability.

 Any taxes or other amounts required to be withheld by the Company by applicable law or regulation shall be paid, at the option of the
Company as follows: 
 (i) through reducing the number of shares of Common Stock actually issued to the Participant in an amount equal to
the statutory minimum of the Participant’s total tax and other withholding obligations due and payable by the Company. Fractional shares will not be retained to satisfy any portion of the Company’s withholding obligation. Accordingly, the
Participant agrees that in the event that the amount of withholding required would result in a fraction of a share being owed, that amount will be satisfied by withholding the fractional amount from the Participant’s paycheck; 

(ii) requiring the Participant to deposit with the Company an amount of cash equal to the amount determined by the Company to be required to
be withheld with respect to the statutory minimum amount of the Participant’s total tax and other withholding obligations due and payable by the Company or otherwise withholding from the Participant’s paycheck an amount equal to such
amounts due and payable by the Company; or 
 (iii) if the Company believes that the sale of shares can be made in compliance with
applicable securities laws, authorizing, at a time when the Participant is not in possession of material nonpublic information, the sale by the Participant on the date of vesting of the RSUs such number of shares of Common Stock as the Company
instructs a broker to sell to satisfy the Company’s withholding obligation, after deduction of the broker’s commission, and the broker shall remit to the Company the cash necessary in order for the Company to satisfy its withholding
obligation. To the extent the proceeds of such sale exceed the Company’s withholding obligation the Company agrees to pay such excess cash to the Participant as soon as practicable. In addition, if such sale is not sufficient to pay the
Company’s withholding obligation the Participant agrees to pay to the Company as soon as practicable, including through additional payroll withholding, the amount of any withholding obligation that is not satisfied by the sale of shares of
Common Stock. The Participant agrees to hold the Company and the broker harmless from all costs, damages or expenses relating to any such sale. The Participant acknowledges that the Company and the broker are under no obligation to arrange for such
sale at any particular price. In connection with such sale of shares of Common Stock, the Participant shall execute any such documents requested by the broker in order to effectuate the sale of shares of Common Stock and payment of the withholding
obligation to the Company. The Participant acknowledges that this paragraph is intended to comply with Section 10b5-1(c)(1)(i)(B) under the Exchange Act. 

  
 5 

 The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied
that all required withholdings have been made. 
 9. No Obligation to Maintain Relationship. The Participant acknowledges that:
(i) the Company is not by the Plan, this Award or this Agreement obligated to continue the Participant as an Employee, director or Consultant of the Company or an Affiliate; (ii) the Plan is discretionary in nature and may be suspended or
terminated by the Company at any time; (iii) the grant of this Award is a one-time benefit which does not create any contractual or other right to receive any other award under the Plan, or benefits in lieu of awards or any other benefits in
the future; (iv) the Participant’s participation in the Plan is voluntary and future awards, if any, will be at the sole discretion of the Company, including, but not limited to, the timing of any grant, the amount of any award, vesting
provisions and purchase price, if any; (vi) the value of this Award is an extraordinary item of compensation which is outside the scope of the Participant’s employment contract, if any; and (vii) the Award is not part of normal or
expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments. 

10. Notices. Any notices required or permitted by the terms of this Agreement or the Plan shall be given by recognized courier service,
facsimile, registered or certified mail, return receipt requested, addressed as follows: 
 If to the Company: 

Amedica Corporation 
 1885 W 2100
South 
 Attn: Chief Legal Officer 

Salt Lake City, UT 84119 
 If to
the Participant: 
 To the address set forth in the Company’s records. 

or to such other address or addresses of which notice in the same manner has previously been given. Any such notice shall be deemed to have been given on the
earliest of receipt, one business day following delivery by the sender to a recognized courier service, or three business days following mailing by registered or certified mail. 

11. Benefit of Agreement. Subject to the provisions of the Plan and the other provisions hereof, this Agreement shall be for the
benefit of and shall be binding upon the heirs, executors, administrators, successors and assigns of the parties hereto. 
 12. Governing
Law. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without giving effect to the conflict of law principles thereof. For the purpose of litigating any dispute that arises under this
Agreement, whether at law or in equity, the parties hereby consent to exclusive jurisdiction in Utah and agree that such litigation shall be conducted in the state courts of Salt Lake City, Utah or the federal courts of the United States for the
District of Utah. 
 13. Severability. If any provision of this Agreement is held to be invalid or unenforceable by a court of
competent jurisdiction, then such provision or provisions shall be modified to the extent necessary to make such provision valid and enforceable, and to the extent that this is impossible, then such provision shall be deemed to be excised from this
Agreement, and the validity, legality and enforceability of the rest of this Agreement shall not be affected thereby. 

  
 6 

 14. Entire Agreement. This Agreement, together with the Plan, constitutes the entire
agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty,
covenant or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change or restrict the express terms and provisions of this Agreement provided, however, in any event, this Agreement shall be subject to and
governed by the Plan. 
 15. Modifications and Amendments; Waivers and Consents. The terms and provisions of this Agreement may be
modified or amended as provided in the Plan. Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the
benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall
be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent. 

16. Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 17. Data
Privacy. By entering into this Agreement, the Participant: (i) authorizes the Company and each Affiliate, and any agent of the Company or any Affiliate administering the Plan or providing Plan record keeping services, to disclose to the
Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the issuance of the Award or shares of Common Stock and the administration of the Plan; (ii) consents to the
collection, use and disclosure of personal information (which may include name, home and business contact information, personal identifiers such as a date of birth and social insurance number for tax reporting purposes, employment, position and
compensation) by the Company for the purpose of administering the Plan, providing Plan recordkeeping services and facilitating the grant of Stock Rights under the Plan including this Award of Restricted Stock Units and consents to the disclosure of
this information by the Company to any Affiliate of the Company for such purposes; and (iii) authorizes the Company and each Affiliate to store and transmit such information in electronic form. The Company is located in, and the Plan will be
administered (in whole or in part) in the United States and some or all of the personal information may become subject to the laws of, and accessible to, the authorities of the United States. 

18. Section 409A. The Award of RSUs evidenced by this Agreement is intended to comply with the nonqualified deferred compensation
rules of Section 409A of the Code and shall be construed accordingly. In any event, the Company makes no representations or warranties and will have no liability to the Participant or to any other person, if any of the provisions of or payments
under this Agreement is determined to constitute nonqualified deferred compensation subject to Section 409A of the Code but that do not satisfy the requirements of that Section. 

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]